Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;97(44):e13067.
doi: 10.1097/MD.0000000000013067.

Banxia Baizhu Tianma decoction for hyperlipidemia: Protocol for a systematic review and meta-analysis

Hairong Cai  1   2 , Yongning Guo  1 , Zicong Zhao  1 , Yanhong Chen  1 , Shuai Zhao  1   2 , Bojun Chen  1
Affiliations

Banxia Baizhu Tianma decoction for hyperlipidemia: Protocol for a systematic review and meta-analysis

Hairong Cai et al. Medicine (Baltimore). 2018 Nov.

Abstract

Background: Hyperlipidemia is one of the most common metabolic diseases worldwide, as well as a leading risk factor for cardio-cerebrovascular diseases. Banxia Baizhu Tianma decoction (BBTD) is widely used for the treatment of hyperlipidemia in China, however, systematic review and meta-analysis regarding its efficacy and safety is lacking. The aim of this protocol of systematic review is to evaluate the effectiveness and safety of BBTD in the treatment of hyperlipidemia.

Methods: We will include the randomized controlled trials estimating the effectiveness and safety of BBTD in the treatment of hyperlipidemia. Data sources will include 5 English databases (PubMed, EMBASE, Cochrane Library, Web of Science, CINAHL) and 4 Chinese databases (CMB, CNKI, VIP, Wanfang database). The literature to be collected will be from the time when databases were established to September 2018. Efficacy will be accepted as the primary outcome, while blood lipid levels and adverse reactions as the secondary outcome. Study selection, data collection, risk of bias assessment, and evaluation of the quality of the evidence will be conducted by 2 × 2 different reviewers. Statistical syntheses will be conducted by using RevMan software V.5.3.

Results: This study will provide a high-quality evidence for BBTD on the treatment of hyperlipidemia from efficacy, serum lipid levels, and adverse reactions.

Conclusion: The result will provide a basis for judging whether BBTD is an effective intervention for the treatment of hyperlipidemia.

Prospero registration number: PROSPERO CRD 42018081359.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Preferred reporting items for systematic review and meta-analysis (PRISMA) flow chart.
See this image and copyright information in PMC

References

    1. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol 2015;9:129–69. - PubMed
    1. Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007;120:S12–8. - PubMed
    1. Martin SS, Blaha MJ, Blankstein R, et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation 2014;129:77–86. - PMC - PubMed
    1. Mcpherson R, Frohlich J, Fodor G, et al. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913–27. - PMC - PubMed
    1. Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocrine Pract 2012;18:269–93. - PubMed